Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
MindMed Announces Positive Results from Phase 2b Anxiety Trial
Big news for LSD fans and MindMed investors as the Phase 2b trial met its primary endpoint, with 50% clinical remission rate in the 100 µg dose group at Week 4
MM-120 (MindMed’s form of LSD) at 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo
The company plans to hold an End-of-Phase 2 meeting with the FDA and initiate a Phase 3 clinical program in the second half of 2024
MAPS Files New Drug Application With FDA for MDMA-Assisted Therapy
“The filing of our NDA is the culmination of more than 30 years of clinical research, advocacy, collaboration and dedication to bring a potential new option to adults living with PTSD, a patient group that has experienced little innovation in decades,” said Amy Emerson, chief executive officer, MAPS PBC. “If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy, which we hope will drive additional investment into new research in mental health.”
Tryp Therapeutics To Be Acquired by Exopharm
Tryp Therapeutics Announces Signing of Definitive Agreement with Exopharm Limited. The deal closes with a purchase price of CAD$0.08 per share. Tryp shareholders are expected to receive 4.52 Exopharm Shares for each one Tryp share held, representing a transaction value of approximately $12.8 million.
US Congress Adds Psychedelics Studies to Defense Bill
Abipartisan group of congressional lawmakers from both the House and the Senate have agreed to add funding for studies of psychedelic therapies into a major defense bill.
The 2024 National Defense Authorization Act (NDAA) passed on Wednesday and included the provision for psychedelics research introduced by Republican lawmakers like Rep. Morgan Luttrell of Texas.
Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen
“While ketamine and serotonergic psychedelics have shown promise for treating certain neuropsychiatric disorders, they are also associated with troublesome side effects and cardiac risks,” said Aaron Koenig, MD, Chief Medical Officer of Delix Therapeutics. “We are encouraged by our preliminary Phase 1 results, which indicate that DLX-001 is safe, well-tolerated, and, as predicted by our preclinical studies, does not produce hallucinogenic, psychotomimetic, or dissociative effects…”
Phase 2 Trial of DLX-001 Expected to Begin in mid-2024
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
